Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
BIOL's Cash to Debt is ranked higher than
92% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. BIOL: No Debt )
BIOL' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: No Debt

Equity to Asset 0.37
BIOL's Equity to Asset is ranked higher than
55% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BIOL: 0.37 )
BIOL' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.91
Current: 0.37

-0.35
0.91
Interest Coverage No Debt
BIOL's Interest Coverage is ranked higher than
83% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. BIOL: No Debt )
BIOL' s 10-Year Interest Coverage Range
Min: 10.46   Max: 9999.99
Current: No Debt

10.46
9999.99
F-Score: 3
Z-Score: -2.68
M-Score: -3.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -32.52
BIOL's Operating margin (%) is ranked higher than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. BIOL: -32.52 )
BIOL' s 10-Year Operating margin (%) Range
Min: -357.14   Max: 14.2
Current: -32.52

-357.14
14.2
Net-margin (%) -34.34
BIOL's Net-margin (%) is ranked higher than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. BIOL: -34.34 )
BIOL' s 10-Year Net-margin (%) Range
Min: -686.67   Max: 39.05
Current: -34.34

-686.67
39.05
ROE (%) -208.04
BIOL's ROE (%) is ranked lower than
54% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. BIOL: -208.04 )
BIOL' s 10-Year ROE (%) Range
Min: -6372.65   Max: 110.88
Current: -208.04

-6372.65
110.88
ROA (%) -57.29
BIOL's ROA (%) is ranked lower than
51% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. BIOL: -57.29 )
BIOL' s 10-Year ROA (%) Range
Min: -282.19   Max: 62.83
Current: -57.29

-282.19
62.83
ROC (Joel Greenblatt) (%) -251.24
BIOL's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. BIOL: -251.24 )
BIOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1266.67   Max: 222.6
Current: -251.24

-1266.67
222.6
Revenue Growth (3Y)(%) 21.30
BIOL's Revenue Growth (3Y)(%) is ranked higher than
93% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BIOL: 21.30 )
BIOL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.9   Max: 105.4
Current: 21.3

-27.9
105.4
EBITDA Growth (3Y)(%) -6.40
BIOL's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. BIOL: -6.40 )
BIOL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.5   Max: 100
Current: -6.4

-49.5
100
EPS Growth (3Y)(%) -8.00
BIOL's EPS Growth (3Y)(%) is ranked higher than
63% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. BIOL: -8.00 )
BIOL' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.3   Max: 148.4
Current: -8

-54.3
148.4
» BIOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BIOL Guru Trades in Q4 2013

Mario Gabelli 91,000 sh (-5.16%)
» More
Q1 2014

BIOL Guru Trades in Q1 2014

John Burbank 20,661 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
Q2 2014

BIOL Guru Trades in Q2 2014

George Soros 30,949 sh (New)
Mario Gabelli 91,455 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

BIOL Guru Trades in Q3 2014

Mario Gabelli 91,455 sh (unchged)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $1.92 - $2.72 $ 2.6517%0
John Burbank 2014-06-30 Sold Out $1.76 - $2.39 $ 2.6530%0
George Soros 2014-06-30 New Buy$1.76 - $2.39 $ 2.6530%30949
John Burbank 2014-03-31 New Buy$2.279 - $3.343 $ 2.65-5%20661
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.60
BIOL's P/B is ranked higher than
54% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. BIOL: 10.60 )
BIOL' s 10-Year P/B Range
Min: 0.87   Max: 42.47
Current: 10.6

0.87
42.47
P/S 1.96
BIOL's P/S is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. BIOL: 1.96 )
BIOL' s 10-Year P/S Range
Min: 0.13   Max: 9.81
Current: 1.96

0.13
9.81
EV-to-EBIT -7.04
BIOL's EV-to-EBIT is ranked lower than
53% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. BIOL: -7.04 )
BIOL' s 10-Year EV-to-EBIT Range
Min: -62.9   Max: 73
Current: -7.04

-62.9
73
Current Ratio 1.41
BIOL's Current Ratio is ranked higher than
51% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. BIOL: 1.41 )
BIOL' s 10-Year Current Ratio Range
Min: 0.63   Max: 8.29
Current: 1.41

0.63
8.29
Quick Ratio 0.75
BIOL's Quick Ratio is ranked lower than
52% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. BIOL: 0.75 )
BIOL' s 10-Year Quick Ratio Range
Min: 0.34   Max: 7.75
Current: 0.75

0.34
7.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.72
BIOL's Price/Tangible Book is ranked higher than
61% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. BIOL: 14.72 )
BIOL' s 10-Year Price/Tangible Book Range
Min: 3.57   Max: 178.9
Current: 14.72

3.57
178.9
Price/Median PS Value 1.11
BIOL's Price/Median PS Value is ranked higher than
77% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. BIOL: 1.11 )
BIOL' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 34.63
Current: 1.11

0.24
34.63
Earnings Yield (Greenblatt) -14.20
BIOL's Earnings Yield (Greenblatt) is ranked higher than
53% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. BIOL: -14.20 )
BIOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 3.7
Current: -14.2

1.4
3.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BTH.Germany,
Biolase Inc was originally formed as Societe Endo Technic, SA ("SET") in 1984 in Marseilles, France. In 1987, SET merged into Pamplona Capital Corp., a public holding company incorporated in Delaware. In 1994, it changed its name to BIOLASE Technology, Inc. and to BIOLASE, Inc. ("BIOLASE") in 2012. The Company is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional ("3-D") printers; products that are focused on technologies that advance the practice of dentistry and medicine. Its proprietary dental laser systems allows dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a dental procedures, including cosmetic, restorative, and complex surgical applications. Its systems are designed to provide performance for many types of dental procedures with less pain and faster recovery times than are generally achieved with drills, scalpels, and other conventional instruments. The Company has clearance from the U.S. Food and Drug Administration (the "FDA") to sell its laser systems in the United States and also have the necessary registration to sell its laser systems in Canada, the European Union, and various other international markets. Its licensed dental imaging equipment and other related products are designed to improve diagnoses, applications, and procedures in dentistry and medicine. It offers two categories of laser system products: WaterLase systems and Diode systems. Its WaterLase system, uses a patented combination of water and laser energy to perform most procedures currently performed using dental drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. It currently has approximately 180 issued and 120 pending U.S. and international patents, the majority of which are related to WaterLase technology and dental and medical lasers.
» More Articles for BIOL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases... Dec 09 2014
BIOLASE Launches New EPIC™ X diode laser in the United States; Now Dentists Can Delight Their... Dec 01 2014
BIOLASE Launches New EPIC™ X diode laser in the United States; Now Dentists Can Delight Their... Dec 01 2014
BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York... Nov 28 2014
BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York... Nov 28 2014
Biolase Announces Management Change Nov 19 2014
Biolase Announces Management Change Nov 19 2014
BIOLASE, INC Financials Nov 15 2014
10-Q for BIOLASE, Inc. Nov 09 2014
BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Nov 07 2014
BIOLASE Reports 2014 Third Quarter Results Nov 04 2014
BIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2014
BIOLASE Reports 2014 Third Quarter Results Nov 04 2014
BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement Nov 04 2014
BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement Nov 04 2014
BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 Oct 23 2014
BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 Oct 23 2014
George Soros Picks KIOR, RSH, BIOL Soar On Monday Sep 15 2014
Biolase management overhauled amid bid to stanch a decade of red ink Sep 14 2014
BIOLASE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Sep 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK